Stay updated on Gantenerumab Long-term Safety in AD Clinical Trial
Sign up to get notified when there's something new on the Gantenerumab Long-term Safety in AD Clinical Trial page.

Latest updates to the Gantenerumab Long-term Safety in AD Clinical Trial page
- Check4 days agoChange DetectedPatch release: Revision updated from v3.0.1 to v3.0.2; Back to Top link removed. No other substantive changes detected.SummaryDifference0.2%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%
- Check19 days agoChange DetectedThe web page has undergone significant updates, including the addition of new facility names and locations, particularly in South Korea, Italy, Poland, and Turkey, while also removing some previously listed locations and related topics. Notably, the MedlinePlus related topic on Alzheimer's Disease has been removed, but new topics related to Alzheimer's caregivers have been added.SummaryDifference12%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check47 days agoChange DetectedThe page has been updated to version v2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1.0%
Stay in the know with updates to Gantenerumab Long-term Safety in AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gantenerumab Long-term Safety in AD Clinical Trial page.